EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA,
RWE and Market Access
The European Union’s Health Technology Assessment framework is transforming how pharmaceutical companies prepare clinical evidence, demonstrate therapeutic value and plan market access across Europe. As Joint Clinical Assessment (JCA) implementation progresses, manufacturers face growing pressure to align clinical development, Real-World Evidence (RWE), Health Economics and Outcomes Research (HEOR), and national reimbursement strategies.
The challenge is no longer simply understanding EU-HTA requirements. It is ensuring that evidence strategies can support both European clinical assessments and national healthcare decision-making.
For pharmaceutical manufacturers, the central question is:
Can one evidence strategy satisfy evolving EU-HTA expectations while supporting different national pricing and reimbursement decisions?
The answer depends on early evidence planning, appropriate comparator selection, robust RWE methodologies, cross-functional collaboration and the responsible use of Artificial Intelligence (AI).
What Is Changing Under EU-HTA in 2026?
The EU Health Technology Assessment Regulation (Regulation (EU) 2021/2282), which began applying on 12 January 2025, established a new framework for cooperation among European Union Member States in assessing health technologies.
Joint Clinical Assessments are being introduced progressively, beginning with new cancer medicines and advanced therapy medicinal products (ATMPs), with additional product categories entering the framework in subsequent years.
The objective is to improve coordination, reduce unnecessary duplication of clinical assessments and strengthen the use of scientific evidence in healthcare decision-making.
However, EU-HTA does not create a single European reimbursement system.
While Joint Clinical Assessment provides a common clinical assessment process, individual Member States retain responsibility for pricing, reimbursement and healthcare resource allocation.
This distinction is particularly important for pharmaceutical Market Access and HEOR teams.
EU-HTA readiness requires more than preparing a JCA dossier. It requires developing evidence that remains relevant to national HTA evaluations and payer expectations.
1. JCA Readiness: Why Clinical Evidence Strategy Must Begin Earlier
One of the biggest challenges in Joint Clinical Assessment preparation is ensuring that clinical development programmes generate evidence relevant to the questions European HTA assessors need answered.
The Population, Intervention, Comparator and Outcomes (PICO) framework plays a central role in defining the scope of clinical assessment.
However, different healthcare systems may have different standards of care, relevant comparators and treatment pathways.
A clinical trial designed primarily around regulatory approval may therefore leave important questions unanswered during subsequent HTA evaluations.
Pharmaceutical manufacturers should consider several priorities:
Comparator selection: Are the treatment alternatives relevant to European clinical practice?
Patient populations: Does the available evidence adequately represent populations of interest to HTA assessors?
Clinical endpoints: Are the selected outcomes meaningful for evaluating relative clinical effectiveness?
Evidence uncertainty: Can limitations in direct and indirect comparative evidence be adequately characterized?
Cross-functional alignment: Are Clinical Development, Regulatory Affairs, HEOR and Market Access teams coordinating evidence requirements early enough?
The strategic challenge is not simply producing more clinical data.
It is ensuring that evidence generated during development can answer the clinical questions that emerge during European assessment and national access decisions.
2. Why a Joint Clinical Assessment Does Not Guarantee Market Access
One of the most important distinctions in European pharmaceutical Market Access is the difference between clinical assessment and reimbursement decision-making.
Joint Clinical Assessment focuses on the relative clinical effectiveness and safety of health technologies.
National authorities remain responsible for determining how clinical findings contribute to local pricing, reimbursement and healthcare funding decisions.
Consequently, even when a medicine has undergone a European JCA, manufacturers may still need to address country-specific requirements relating to:
Cost-effectiveness and budget impact.
Local treatment pathways and comparator relevance.
Healthcare system affordability.
Patient access criteria.
Uncertainty in long-term clinical outcomes.
National pricing and reimbursement negotiations.
This creates a major strategic consideration for pharmaceutical companies operating across multiple European markets.
A coordinated European clinical evidence strategy must be complemented by a flexible national Market Access strategy.
Organizations that treat JCA preparation and national reimbursement planning as entirely separate activities risk creating avoidable evidence gaps, duplication and delays.
3. Real-World Evidence in EU-HTA: Moving From Data Availability to Decision-Grade Evidence
Real-World Evidence is increasingly relevant to pharmaceutical development, regulatory science and health technology assessment.
RWE can be generated through the analysis of Real-World Data (RWD), including electronic health records, disease registries, insurance claims and other routinely collected healthcare information.
Potential applications include:
Understanding treatment patterns in routine clinical practice.
Evaluating long-term outcomes and treatment effectiveness.
Supporting external comparator studies where appropriate.
Characterizing patient populations and unmet medical needs.
Investigating safety outcomes and healthcare resource utilization.
However, the availability of extensive healthcare datasets does not automatically make evidence suitable for HTA decision-making.
Important methodological challenges include selection bias, confounding, missing data, limited follow-up and differences between healthcare systems.
For RWE to support credible evidence assessment, manufacturers must establish clear research questions, appropriate study designs and transparent analytical methods.
The future of RWE in Market Access will depend less on the quantity of available data and more on whether the evidence is reliable, relevant and fit for its intended decision-making purpose.
DARWIN EU and the Evolution of European Real-World Data
The European Medicines Agency’s Data Analysis and Real World Interrogation Network (DARWIN EU) supports the generation of evidence from real-world healthcare databases for regulatory decision-making.
Its development illustrates the increasing importance of distributed healthcare data networks, standardized research approaches and evidence quality.
Although regulatory RWE and HTA evidence requirements are not identical, developments in European data infrastructure are relevant to organizations seeking to strengthen evidence generation capabilities.
For pharmaceutical manufacturers, the key consideration is how to integrate high-quality RWD into broader evidence strategies while respecting data governance, privacy and methodological requirements.
4. AI in HEOR and Market Access: Can Faster Evidence Generation Deliver Better Decisions?
Artificial Intelligence is becoming increasingly relevant to pharmaceutical evidence generation and Market Access operations.
AI-enabled tools can support activities such as scientific literature screening, evidence identification, data processing, information extraction, market intelligence and the preparation of analytical workflows.
These capabilities offer opportunities to improve operational efficiency across HEOR, RWE and HTA teams.
However, the adoption of AI introduces important questions concerning scientific reliability and governance.
Can AI-assisted evidence generation meet the transparency, reproducibility and methodological expectations of European HTA assessors?
The answer depends on how AI is implemented, validated and supervised.
Pharmaceutical companies should consider:
Data quality: AI outputs depend on the relevance and reliability of underlying data.
Methodological transparency: Analytical assumptions, model limitations and evidence-generation processes must remain understandable and appropriately documented.
Human oversight: Qualified experts must retain responsibility for scientific interpretation and validation.
Reproducibility: Evidence-generation processes should support verification and quality assurance.
Regulatory and HTA relevance: AI applications should be evaluated against the specific requirements of their intended use.
The objective should not be to automate every evidence-generation activity.
AI should strengthen evidence quality and decision-making, not merely accelerate the production of documents and analyses.
5. Pricing and Reimbursement Under Pressure: What Payers Expect From Pharma
Pharmaceutical pricing and reimbursement decisions increasingly require manufacturers to communicate clinical value alongside economic and healthcare system considerations.
National payers may evaluate medicines using different approaches to comparative effectiveness, cost-effectiveness, budget impact and uncertainty.
For Market Access leaders, this creates a need to connect evidence generation with payer-relevant value communication.
Important strategic considerations include:
Demonstrating meaningful clinical benefits against relevant alternatives.
Understanding the economic implications of new treatments.
Communicating uncertainty in clinical and economic evidence.
Addressing patient-relevant outcomes and unmet medical needs.
Preparing for country-specific evidence requirements.
Evaluating the role of outcomes-based reimbursement arrangements where appropriate.
The challenge becomes particularly complex for innovative therapies, oncology products and rare disease treatments where long-term evidence may be limited at launch.
A strong clinical evidence package is essential, but successful Market Access also depends on how that evidence addresses national payer priorities.
6. Building an Integrated Evidence Strategy for 2027 and Beyond
The evolving EU-HTA landscape creates an opportunity for pharmaceutical companies to rethink how evidence is planned, generated, managed and communicated.
Rather than operating through disconnected functions, organizations may benefit from an integrated evidence strategy connecting Clinical Development, Regulatory Affairs, HEOR, RWE, Medical Affairs and Market Access.
Five capabilities deserve particular attention.
1. Early HTA evidence planning
Identify potential evidence requirements before pivotal clinical development decisions become difficult to change.
2. Cross-functional collaboration
Establish clear governance and accountability across clinical, regulatory, evidence and commercial access functions.
3. Robust comparative evidence
Develop appropriate strategies for addressing comparator differences, indirect comparisons and evidence uncertainty.
4. Digital evidence infrastructure
Invest in reliable data systems and validated analytical tools that support efficient evidence management and reuse.
5. National Market Access preparedness
Ensure European clinical assessment evidence can inform local value communication, reimbursement submissions and payer engagement.
Together, these capabilities can help manufacturers develop more consistent and adaptable evidence strategies.
Frequently Asked Questions About EU-HTA, JCA and Market Access
What is EU-HTA in 2026?
EU-HTA refers to the European Union’s framework for coordinated health technology assessment under Regulation (EU) 2021/2282. In 2026, the framework is in its early implementation phase, with Joint Clinical Assessments applying to designated categories of medicines and further expansion scheduled in subsequent years.
What is the difference between JCA and national HTA?
Joint Clinical Assessment provides a coordinated European assessment of relative clinical effectiveness and safety. National HTA and reimbursement processes may additionally consider economic value, budget impact and country-specific healthcare priorities.
Can Real-World Evidence be used in Joint Clinical Assessment?
RWE may contribute to relevant clinical evidence questions where suitable, depending on the assessment context, data quality and methodological appropriateness. Its usefulness must be evaluated against the specific evidence requirements and uncertainties involved.
How can AI support HEOR and Market Access?
AI can support literature screening, evidence management, data processing, analytical workflows and Market Access intelligence. However, scientific validation, methodological transparency and expert oversight remain necessary.
Why is PICO important for EU-HTA?
PICO defines the population, intervention, comparator and outcomes relevant to a clinical assessment. It helps establish the evidence questions that manufacturers need to address during Joint Clinical Assessment.
Does a successful JCA guarantee reimbursement across Europe?
No. Joint Clinical Assessment does not replace national pricing and reimbursement decisions. Individual Member States retain responsibility for determining access and funding within their healthcare systems.
European RWE & Market Access Summit 2026: Turning Evidence Into Access
As pharmaceutical companies navigate evolving EU-HTA requirements, the need for practical collaboration between evidence generation, HTA and Market Access functions continues to grow.
These challenges will be explored at the 2nd Annual European RWE & Market Access Summit 2026 – JCA & PICO Strategy Edition, taking place on 21–22 October 2026 at Inntel Hotels Amsterdam Landmark, Amsterdam, Netherlands.
The summit brings together senior leaders and experts from pharmaceutical companies, Real-World Evidence, HEOR, HTA, Pricing & Reimbursement, Medical Affairs and healthcare technology.
Key Discussions at the Summit
EU-HTA and JCA: First Wave of Experience and Its Impact on Access
RWE That Influenced HTA Decisions: Lessons From Recent Submissions
DARWIN EU 2.0 and EU-HTA: What Manufacturers Must Know
How AI Is Transforming JCA Preparation: Practical Use Cases and Lessons Learned
Pricing and Reimbursement Under Pressure
JSC and National HTA Consultations: How Should Pharma Sequence Early Advice for JCA and Market Access?
Access 2030 Pathways: Preparing Evidence and Market Access Teams for the Future
Through expert-led presentations, case studies, panel discussions and networking opportunities, participants will explore how evidence strategies can be translated into practical approaches to pharmaceutical Market Access.
Conclusion: The Future of EU-HTA Is About Evidence Readiness
The implementation of EU-HTA represents more than a regulatory milestone.
It is encouraging pharmaceutical organizations to rethink how clinical evidence, Real-World Evidence, health economics and Market Access strategy work together.
As Joint Clinical Assessment implementation progresses, organizations must balance European evidence requirements with the realities of national healthcare decision-making.
The pharmaceutical companies best positioned for the next phase of European HTA will be those capable of generating credible evidence, managing uncertainty and connecting scientific outcomes with real-world access decisions.
Join the Conversation in Amsterdam at the European RWE & Market Access Summit 2026
European RWE & Market Access Summit 2026 – JCA & PICO Strategy Edition
Date: 21–22 October 2026
Venue: Inntel Hotels Amsterdam Landmark, Amsterdam, Netherlands
Request the agenda here : https://wlcus.com/event/rwe_market_access_event_2026/
Click here to register: https://wlcus.com/event/rwe_market_access_event_2026/#Registration
Contact: booking@wlcus.com
Website: https://wlcus.com